Answers are grounded in this paper and cite their sources.
Review discusses boosting microbiota-derived metabolites to improve cancer therapy outcomes, indicating potential benefits for patients.
The gut microbiome exerts distant and local effects on tumours, healthy epithelial cells, and the immune system through the production of bioactive metabolites. This influences cancer therapy responses across treatment modalities and cancer types. In this review, we discuss promising approaches to boost beneficial microbiota-derived metabolites to enhance existing cancer therapies, including prebiotics, probiotics, postbiotics, and live biotherapeutic products. Each approach faces challenges in achieving physiological concentrations and tissue distribution, as well as different regulatory regimes and commercial landscapes. With promising early clinical trials and significant scientific and commercial activity in these areas, there is hope that targeted, metabolite-focused interventions will soon benefit cancer patients.
No takes yet. Share an insight, caveat, or question.
Kamrad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: